Navigation Links
Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/6/2008

SAN DIEGO, Feb. 6 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIO CEO & Investor Conference on February 12, 2008 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. David A. Walsey, Arena's Director of Corporate Communications, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
2. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
3. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
4. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
5. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
7. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
8. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Applied DNA Sciences, Inc. (OTCQB: ... and product authentication solutions, will host a conference call ... third quarter results. The Quarterly Report on Form 10Q ... of the day on Monday August 11, 2014. ... conference call beginning at 9:00 A.M. Eastern Daylight Time ...
(Date:8/1/2014)... August 01, 2014 RURO, Inc., ... provider, today officially announces the opening of its ... Science Park, Baoshan District in Shanghai, PRC, RURO ... under the management of Mr. Shen Gang, the ... the past three years, RURO’s has installed FreezerPro-based ...
(Date:8/1/2014)... , Aug. 1, 2014 One of the ... of personalized medicine, which is the practice of using ... to a patient,s individual biology. Personalized diagnostics—laboratory analyses that ... role in the lab,s future. This fall, AACC ... the latest science in this exciting field and the ...
(Date:8/1/2014)... Research and Markets has announced the addition ... and Analysis Market 2014-2018" report to their offering. ... Single Nucleotide Polymorphism (SNP) genotyping is the screening and ... of various species. SNPs are commonly present in all ... analyze thousands of SNPs and has the potential for ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3RURO Opens Office in Shanghai, China 2First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2
... COLUMBIA, Md., Dec. 14 A&G Pharmaceutical announced,today ... Initiative,has awarded A&G an $870,000 grant to conduct ... proprietary breast cancer biomarker,GP88, in blood and tissue ... could provide the basis for developing a blood ...
... Embla Systems, a leader in the field of,sleep ... of an,exclusive agreement with the Beth Israel Deaconess ... Pulmonary Coupling (CPC) technology,developed by Drs. Robert Thomas, ... CPC technology represents a breakthrough in how sleep ...
... New Mexico, December 13, 2007In collaboration with the ... international team of researchers has, for the first ... mysterious metallic puddles that facilitate the transition of ... one. , The research may lead to a ...
Cached Biology Technology:A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 2A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 3Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology 2Collaboration yields 'the right glasses' for observing mystery behavior in electrons 2Collaboration yields 'the right glasses' for observing mystery behavior in electrons 3
(Date:8/1/2014)... Charan Ranganath of the UC Davis Center for ... National Security Science and Engineering Faculty Fellowship from ... million fellowship will support new work on learning ... UC Davis. , The new project aims to ... with activity in the cortex and hippocampus, brain ...
(Date:8/1/2014)... is tricky enough. Knowing what causes them at the ... of Iowa researchers have created the most detailed map ... long associated with blinding diseases, such as age-related macular ... in the choroid, which supplies blood and oxygen to ... differences in the abundance of proteins in different areas ...
(Date:8/1/2014)... 2014 The Journal of Nutrition Education and Behavior ... Educational Material (GEM) awards, which were presented at the ... "Nutrition Education Impact: Local to Global," in Milwaukee, Wisconsin, ... awards recognize the authors of the best article and ... by members of the JNEB Journal Committee and Board ...
Breaking Biology News(10 mins):A map for eye disease 2
... and Avalon Technology partner on new ... aviation-related ... Inc.,(OTC Bulletin Board: CTHH) ( http://www.catcherinc.com ), a leader ... Technology ( http://www.avalontechnology.com ), a leading,integrator of managed mobile ...
... resulting from higher CO2 could boost the amount ... new study looks at a poorly understood process ... Sayer, postdoctoral fellow at the Smithsonian Tropical Research ... University of Minnesotas Department of Ecology, Evolution and ...
... Boulder, CO, USA Two hundred years ago Lewis and ... deal of scientific research with its descriptions of territory acquired ... be disappointed by the absence of living megafauna, the area ... volume published by the Geological Society of America makes clear ...
Cached Biology News:CATCHER to be Deployed at Major U.S. Airline 2CATCHER to be Deployed at Major U.S. Airline 3CATCHER to be Deployed at Major U.S. Airline 4Complex carbon picture clearer 2
Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
... the HECT protein, E6-AP and ... suggests that this E2 is ... of non-""N-end rule"" protein substrates ... proteins as well as the ...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Biology Products: